Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
暂无分享,去创建一个
G. Salles | Claire L. Simons | S. Wade | G. Hess | I. Kloos | C. Bennison | S. Petersohn | Michael Wang | W. Peng | R. Siddiqi | Jim Wu | Gab Castaigne